9/18/2023 0 Comments Nocturnal lagophthalmos herbal![]() ![]() ![]() In the years following publication of the original TFOS Dry Eye Workshop (DEWS) Management and Therapy Report, there has been a growing realization of the important contribution of meibomian gland dysfunction (MGD) to both symptoms and signs of DED. Comments and suggested revisions were discussed by the subcommittee members and incorporated into the report where deemed appropriate by consensus.Īdvances in our understanding of the risk factors, etiology and pathophysiology of DED have contributed to an evolution in treatment strategies over time. The report was reviewed by all subcommittee members and made available for constructive critique by the entire Tear Film and Ocular Surface Society's Dry Eye Workshop II (TFOS DEWS II) membership. In some instances, due to the relatively recent introduction of the therapy under discussion, this was not possible. Wherever possible, peer-reviewed publications, rather than abstracts, have been used to guide management recommendations. The level of evidence for supporting data from the literature is evaluated according to the modified American Academy of Ophthalmology Preferred Practices guidelines (Table 1). The goals of this committee were to review appropriate methods for the management of DED and recommend a strategy for their clinical application, based on an evidence-based review of the literature. This report summarizes the management and therapeutic options for treating dry eye disease (DED). Keywords: Dry eye disease Dry eye workshop Management TFOS DEWS II Therapy 1. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes.įurther evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. ![]() | Download this report in PDF format | A bstract Management of psychological aspects of DED Wakamatsu, MD, PhD, Jianjiang Xu, MD, PhD, James S. Dong, MD, Gerd Geerling, MD, FEBO, Richard Yudi Hida, MD, Yang Liu, MD, Kyoung Yul Seo, MD, PhD, Joseph Tauber, MD, Tais H. Benitez-del-Castillo, MD, PhD, Reza Dana, MD, Sophie X. Downie, BOptom, PhD,, Donald Korb, OD, Jose M. TFOS DEWS II - Management and Therapy Lyndon Jones, FCOptom, PhD1,'Correspondence information about the author FCOptom, PhD Lyndon JonesEmail the author FCOptom, PhD Lyndon Jones, Laura E. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |